The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma.
Sign Up to like & getrecommendations! Published in 2021 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001041
Abstract: The combination of bortezomib (Velcade, PS-341) and lenalidomide (Revlimid) for the treatment of multiple myeloma was proved by USA Food and Drug Administration in 2006. Lenalidomide prevents the proliferation of multiple myeloma cells through binding… read more here.
Keywords: myeloma; multiple myeloma; pharmacological mechanisms; paradoxical pharmacological ... See more keywords